Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movymia

Allergan logo

Allergan stumps up $375m for bolt-on acquisitions

Firm has recently added two migraine drugs and Oculeve to its portfolio

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo wins anti-PD1 race in Europe

Treatment given the EMA nod of approval for melanoma

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Former Sanofi UK MD to head Teva UK

Steve Oldfield has been named as the firm’s new general manager

- PMLiVE

Patients ‘sceptical’ about biosimilars, says EULAR

Concerns for safety of drugs for arthritis and other musculoskeletal diseases

- PMLiVE

Praluent and Repatha backed for approval in US

Sanofi and Amgen remain in fierce competition in PCSK9 inhibitors

EISAI

Eisai launches thyroid cancer therapy Lenvima in UK

The UK is its first European market, with wider EU roll out expected in coming months

Biomarin

BioMarin files muscular dystrophy drug in EU

Drisapersen could be the first ‘exon-skipping’ therapy

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

Sanofi reception

Sanofi and Amgen poised for cholesterol drug sales

Praluent to be assessed by FDA advisory committee later this week

- PMLiVE

Sanofi rare disease drug a breakthrough, says FDA

Regulator awarded the status to olipudase alfa for metabolic disorder

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links